Patricia Carr sold $798k of JAZZ
SVP, Chief Accounting Officer at Jazz Pharmaceuticals plc. 4,660 shares at an average of $171.20, traded Dec 5, 2025, filed Dec 9, 2025.
Score components
- +15RoleOfficer
- +22Trade size$798k at market
- +20Share of holdings soldSold 65% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.2%, 3m +14.6%, 6m +41.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001784606-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | SOpen-market sale Ordinary Shares | -160 | $171.11 | $27k | 7,012 | Dec 9, 2025 |
| Dec 5, 2025 | MOption exercise Ordinary Shares | +4,500 | $140.67 | $633k | 11,512 | Dec 9, 2025 |
| Dec 5, 2025 | SOpen-market sale Ordinary Shares | -4,500 | $171.20 | $770k | 7,012 | Dec 9, 2025 |
| Dec 5, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -4,500 | $0.00 | $0 | 0 | Dec 9, 2025 |
Related signals
Other insiders at Jazz Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $473k 2,000 shares | -1% | |
| 28Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $289k 1,200 shares | -2% | |
| 38Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $486k 2,000 shares | -1% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 40Moderate | Jazz Pharmaceuticals plc | Robert Iannone EVP, Global Head of R&D & CMO | $19M 76,921 shares | -54% | |
| 20Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 20Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 28Weak | Jazz Pharmaceuticals plc | Mark Douglas Smith director | $267k 1,157 shares | -11% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $278k 1,200 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.